Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02730247 | Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 7 | Liza Villaruz, MDOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT00415363 | Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy | completed | Phase 2 | 109 | Eli Lilly and CompanyINDUSTRY | 5 | Nov 5, 2020 |
| clinicaltrials |
| NCT00723957 | A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer | completed | Phase 2 | 260 | R-PharmINDUSTRY | 10 | Oct 28, 2020 | clinicaltrials |
| NCT02785913 | Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | completed | Phase 2 | 31 | SWOG Cancer Research NetworkNETWORK | 2 | Oct 23, 2020 | clinicaltrials |
| NCT00553254 | Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer | completed | Phase 2 | 55 | PfizerINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT01702844 | Single Arm on the Tolerability of Weekly Nab-paclitaxel | completed | Phase 2 | 42 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT01532089 | Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations | completed | Phase 2 | 88 | Academic and Community Cancer Research UnitedOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT02879760 | Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients | completed | Phase 1 / Phase 2 | 16 | Turnstone Biologics, Corp.INDUSTRY | 1 | Oct 6, 2020 | clinicaltrials |
| NCT00835471 | 2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)(NVALT10) | completed | Phase 2 | 195 | Dutch Society of Physicians for Pulmonology and TuberculosisOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT01171170 | Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer(NVALT12) | completed | Phase 2 | 223 | Dutch Society of Physicians for Pulmonology and TuberculosisOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT00950365 | Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 79 | Albert Einstein College of MedicineOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT03450330 | Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer(JACKPOT1) | completed | Phase 1 / Phase 2 | 10 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 24, 2020 | clinicaltrials |
| NCT02499770 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) | completed | Phase 1 / Phase 2 | 122 | G1 Therapeutics, Inc.INDUSTRY | 7 | Aug 21, 2020 | clinicaltrials |
| NCT01218516 | A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung | completed | Phase 2 | 130 | MorphotekINDUSTRY | 8 | Aug 20, 2020 | clinicaltrials |
| NCT03086733 | Phase II Lung Metcore - Preoperative Metformin for Lung Cancer(Metcore) | completed | Phase 2 | 28 | University Health Network, TorontoOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT02492568 | Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC(PEMBRO-RT) | completed | Phase 2 | 92 | The Netherlands Cancer InstituteOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT01833143 | Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D | completed | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 4, 2020 | clinicaltrials |
| NCT02490696 | Comparative Study of the Hypoxia Measured in FAZA and F-miso PET/CT Scan in Patients With Non-small Cell Lung Cancer(RTEP6) | completed | Phase 2 | 23 | Centre Henri BecquerelOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT00866970 | Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia | completed | Phase 2 | 124 | CSL BehringINDUSTRY | 9 | Jul 9, 2020 | clinicaltrials |
| NCT00530621 | Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer | completed | Phase 2 | 160 | Eli Lilly and CompanyINDUSTRY | 6 | Jul 1, 2020 | clinicaltrials |
| NCT01941654 | ATOM_local Ablative Therapy | completed | Phase 2 | 18 | Chinese University of Hong KongOTHER | 1 | Jun 18, 2020 | clinicaltrials |
| NCT01101334 | Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 90 | Daiichi SankyoINDUSTRY | 4 | Jun 16, 2020 | clinicaltrials |
| NCT00073398 | Vaccine Treatment for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 54 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT01380769 | A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 157 | NewLink Genetics CorporationINDUSTRY | 2 | May 28, 2020 | clinicaltrials |
| NCT00915005 | Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence | completed | Phase 2 | 275 | M.D. Anderson Cancer CenterOTHER | 1 | May 26, 2020 | clinicaltrials |
| NCT03472053 | A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 60 | BioMarck Pharmaceuticals, Ltd.INDUSTRY | 1 | May 19, 2020 | clinicaltrials |
| NCT02289690 | Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 221 | AbbVieINDUSTRY | 12 | May 14, 2020 | clinicaltrials |
| NCT00806286 | Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 111 | Daiichi SankyoINDUSTRY | 4 | May 13, 2020 | clinicaltrials |
| NCT01671332 | Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 80 | University of Wisconsin, MadisonOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT00271505 | Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer | completed | Phase 2 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | May 11, 2020 | clinicaltrials |
| NCT02221739 | Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 39 | NYU Langone HealthOTHER | 1 | May 11, 2020 | clinicaltrials |
| NCT03704870 | Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection | completed | Phase 2 | 50 | University Health Network, TorontoOTHER | 1 | May 1, 2020 | clinicaltrials |
| NCT00080015 | Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 9 | IpsenINDUSTRY | 0 | Apr 29, 2020 | clinicaltrials |
| NCT02848651 | A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer(B-F1RST) | completed | Phase 2 | 153 | Genentech, Inc.INDUSTRY | 1 | Apr 28, 2020 | clinicaltrials |
| NCT02336451 | A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges(Ascend-7) | completed | Phase 2 | 156 | Novartis PharmaceuticalsINDUSTRY | 17 | Apr 21, 2020 | clinicaltrials |
| NCT03499834 | A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy(IVY03) | completed | Phase 2 | 26 | Ivy Life Sciences, Co., LtdINDUSTRY | 1 | Apr 16, 2020 | clinicaltrials |
| NCT02573506 | Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung Cancer | completed | Phase 2 | 99 | Sun Yat-sen UniversityOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT00137800 | Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients | completed | Phase 2 | 82 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT01773109 | Etirinotecan Pegol (NKTR-102) in NSCLC | completed | Phase 2 | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT01876446 | Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer | completed | Phase 2 | 38 | Roswell Park Cancer InstituteOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT02735980 | A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer | completed | Phase 2 | 133 | Eli Lilly and CompanyINDUSTRY | 10 | Mar 17, 2020 | clinicaltrials |
| NCT02544633 | Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET | completed | Phase 2 | 68 | Mirati Therapeutics Inc.INDUSTRY | 9 | Mar 4, 2020 | clinicaltrials |
| NCT03652857 | Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer | completed | Phase 2 | 30 | Yongchang ZhangOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02590965 | A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 91 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT00613626 | Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 74 | Hoosier Cancer Research NetworkOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02551432 | Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer(MISP-MK3475) | completed | Phase 2 | 26 | Seoul National University HospitalOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT03155009 | A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer(ATALK) | completed | Phase 2 | 44 | Hoffmann-La RocheINDUSTRY | 1 | Feb 10, 2020 | clinicaltrials |
| NCT01933347 | Third-line Treatment of Gefitinib in NSCLC Patients | completed | Phase 2 | 46 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT01065441 | Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer | completed | Phase 1 / Phase 2 | 9 | Michael Har-NoyINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01310244 | MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC | completed | Phase 1 / Phase 2 | 23 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 6, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Nov 19, 2020source: clinicaltrials